As the use of medications to support weight loss continues to rise, we see an opportunity to serve those consumers
Unsurprisingly, not every new AOM asset delivered on those expectations in subsequent phase 2 or phase 3 trials, let alone setting ever more spectacular benchmarks for weight loss, while investors increasingly recognised the importance of a clean tolerability profile alongside compelling efficacy [1]
doi:10.14309/ajg.00000000000003525 65
With expert guidance and monitoring, you can minimize risks like hair shedding, optimize your nutrition, and maintain healthy, sustainable results
Therefore, individualized initiation thresholds, gradual dose titration, and periodic assessment of muscle mass and bone densityan issue recently highlighted in relation to GLP-1 therapy [104] are critical when treating older or frail patients